United Kingdom

People: Achillion Pharmaceuticals Inc (ACHN.OQ)

ACHN.OQ on NASDAQ Stock Exchange Global Select Market

16 Aug 2019
Change (% chg)

$0.05 (+1.06%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Firuta, Paul 

Mr. Paul F. Firuta is Chief Operating Officer, Executive Vice President of the Company. Mr. Firuta has served as our Executive Vice President and Chief Operating Officer since September 2018. Prior to joining Achillion in September 2018, Mr. Firuta served as Chief Commercial Officer of uniQure N.V., a gene therapy company, from May 2016 to June 2018. Prior to joining uniQure, N.V., Mr. Firuta was Chief Commercial Officer of BioBlast Pharma, Ltd., an orphan disease-focused biotechnology company, from August 2015 to May 2016. From March 2014 to February 2015, Mr. Firuta was President, US Commercial Operations of NPS Pharma, a biopharmaceutical company, and from October 2008 to February 2014, Mr. Firuta was Vice President and General Manager, Americas, of ViroPharma, Inc., a biopharmaceutical company, both of which were acquired by Shire Pharmaceuticals in 2015 and 2014, respectively. Mr. Firuta has also held positions at LEV Pharmaceuticals, Inc., a biopharmaceutical company, OraPharma, a specialty pharmaceutical company, and SmithKline Beecham Pharmaceuticals, a pharmaceutical company. Mr. Firuta holds an M.B.A. from St. Joseph’s University and a B.S. from King’s College.

Basic Compensation

Total Annual Compensation, USD 174,580
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 924,123
Fiscal Year Total, USD 1,098,700

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Nicole Vitullo


Joseph Truitt


Brian Di Donato


Paul Firuta


Martha Manning


Anthony Gibney

As Of  31 Dec 2018